IR Materials –1H FY3/26–

November 10, 2025

Nipro Corporation

Table of Contents

Business Overview-- 3
H1 FY3/26 Results-- 4
SG&A Expenses: Major Accounts-------------------------------------- 5
Research and Development Expenses---------------------------------- 6
Capex and Depreciation-- 7
P/L comparison excluding forex impact------------------------------- 8
Segment Sales and Segment Profit------------------------------------9
(1) Medical-Related Segment Sales (Domestic)---------------------10
(1) Medical-Related Segment Sales (Overseas) ---------------------11
(2) Pharmaceutical-Related Segment Sales ------------------------12
(3) PharmaPackaging Segment Sales--------------------------------13
Exchange rate, sensitivity / Product Category-----------------------13
Net Sales by Segment and Product Category-----------------------15
Net Sales by Segment and Region-------------------------------------16
Net Sales by Product Category-----------------------------------17,18

Business Overview

Manufacturing

The new installation of dialyzer lines (Odate, Akita) in FY03/26 is shown below.
The 11th line at the Odate, Akita Plant starts operation in April 2025, and the 7th line for FB dialyzers starts operation in October 2025.

2025												2026			
1	2	3	4	5	6	7	8	9	10	11	12	1~3	4~6	7~9	10~12
			Odate Plant Dialyzers 11th line began operations						**Odate Plant** FB Dialyzers 7th line began operations				**Vietnam** Dialyzers 1st line will began operations		**Vietnam** Dialyzers 2nd line will began operations

Sales

Dialysis medical devices
Domestic sales decreased YoY due to limited shipment of the Fineflux product.
For overseas sales, while Asia remained flat YoY, sales increased in the Americas due to continued stable orders for dialyzers and dialysis equipment, in Europe due to increased demand for high-performance dialyzers, and in China due to increased sales volume of dialyzers resulting from centralized procurement.

Vascular-related products
Domestic sales recovered and increased due to market expansion for drug-eluting balloons.
In addition, sales increased due to strong performance of balloon catheters, which were launched in earnest.
Overseas sales remained strong in Europe.

Pharmaceuticals (own brand)
Oral drugs decreased due to product consolidation and falling drug prices. External preparations and patches also decreased, despite a partial recovery in supply volumes, as they continued to be impacted by Budepor inhalation powder and Loxoprofen tape. Injectables and infusions increased due to strong shipment performance.

Pharmaceuticals (contract manufacturing)
Despite higher sales of anticancer drugs compared to the previous year, along with growth in new contract products and the passing on of costs for existing products, overall sales decreased year-on-year, mainly attributable to reduced volumes of certain long-listed drugs under the Selected Medical Care System and the discontinuation of certain contract products.

PharmaPackaging
Glass tubing and dental related products achieved sales growth in domestic sales, meanwhile severely impacted businesses of vials in the U.S. and sterile syringes in Europe, resulting in an overall decrease compared to previous year.

H1 FY3/26 Results

(¥ 100 million)	H1 FY03/25	H1 FY03/26	Change (Change %)	FY03/26 Forecast (Profit ratio)	Quarterly Results FY03/25 Q2	Quarterly Results FY03/25 Q3	Quarterly Results FY03/25 Q4	Quarterly Results FY03/26 Q1	Quarterly Results FY03/26 Q2
Net sales	3,120.1	**3,173.8**	+53.6 +1.7%	**6,770.0**	**1,600.3**	**1,672.6**	**1,653.0**	**1,592.2**	**1,581.6**
Cost of sales	2,176.7	**2,172.6**	-4.1 -0.2%	**4,710.0**	**1,111.8**	**1,158.8**	**1,201.4**	**1,090.6**	**1,081.9**
Gross profit (※1)	943.4	**1,001.1**	+57.7	**2,060.0**	**484.3**	**513.8**	**451.6**	**501.5**	**499.6**
	30.2%	31.5%	+6.1%	30.4%	30.3%	30.7%	27.3%	31.5%	31.6%
SG&A expenses	808.8	**847.8**	+39.0	**1,690.0**	**407.6**	**426.3**	**407.6**	**429.4**	**418.3**
	25.9%	26.7%	+4.8%	25.0%	25.5%	25.5%	24.7%	27.0%	26.5%
Operating profit	134.5	**153.3**	+18.7	**370.0**	**76.7**	**87.4**	**43.9**	**72.1**	**81.2**
	4.3%	4.8%	+14.0%	5.5%	4.8%	5.2%	2.7%	4.5%	5.1%
Ordinary profit (※2)	44.9	**82.3**	+37.4	**242.0**	**-19.2**	**95.1**	**-31.9**	**35.1**	**47.1**
	1.4%	2.6%	+83.3%	3.6%	-1.2%	5.7%	-1.9%	2.2%	3.0%
Profit attributable to owners of parent	1.2	**59.0**	+57.7	**129.5**	**-24.9**	**64.6**	**-14.8**	**32.7**	**26.3**
	0.0%	1.9%	+4468.4%	1.9%	-1.6%	3.9%	-0.9%	2.1%	1.7%

(*1) Effect of unrealized gains on gross profit
H1 FY03/25 -¥2,350 million
H1 FY03/26 +¥1,100 million

(*2) Foreign exchange gains
H1 FY03/25 -¥4,700 million
H1 FY03/26 -¥1,300 million

Net sales | Net sales increased by ¥5,360 million YoY, due to strong sales of dialyzers in the Americas, Europe, and China in overseas medical-related businesses and higher sales of SafeTouch PSV in B2B operations.

Gross profit | Gross profit as a whole increased by ¥5,770 million YoY due to price pass-through and discontinuation of loss-making products while labor costs increased, raw material costs were restrained.

Operating profit | Operating profit increased by ¥1,870 million YoY, as higher net sales and restrained raw material costs more than offset the increase in SG&A expenses, which rose due to higher labor costs both domestic and overseas, as well as higher transportation expenses in North, Central, and South America and Europe.

Ordinary profit | Ordinary profit increased by ¥3,740 million YoY due to ¥1,300 million of foreign exchange loss was recorded this fiscal year, whereas ¥4,700 million of foreign exchange loss was recorded in the previous fiscal year, resulting in a ¥3,400 million reduction in foreign exchange losses.

Profit | Profit increased by ¥5,770 million YoY due to the transfer of land for the regenerative medicine R&D and manufacturing base (Tokyo CPF※) (facilities continue to be used under a lease agreement, with no change in operations) resulted in a gain on sale of fixed assets of ¥4,450 million. *CPF : Cell Processing Facility

SG&A Expenses: Major Accounts

(¥ 100 million)	H1 FY03/25	H1 FY03/26 Actual	H1 FY03/26 % of Total	Change (Change %)	FY03/26 Forecast (Achievement %)
Personnel	263.8	**282.5**	33.3%	+18.7 +7.1%	**565.3** 50.0%
R&D (*1)	103.2	**105.6**	12.5%	+2.4 +2.4%	**208.2** 50.8%
Transportation	74.5	**83.7**	9.9%	+9.1 +12.3%	**176.9** 47.3%
Depreciation (*2)	75.9	**70.7**	8.3%	-5.2 -6.9%	**155.1** 45.6%
Commission expenses (*3)	49.3	**53.2**	6.3%	+3.9 +7.9%	**109.7** 48.6%
Promotion (*4)	44.3	**50.1**	5.9%	+5.8 +13.1%	**84.1** 59.6%
Travel & transportation	22.1	**24.6**	2.9%	+2.4 +11.1%	**51.3** 48.0%
Storage	19.6	**20.4**	2.4%	+0.8 +4.3%	**39.0** 52.5%
Others	155.7	**156.5**	18.5%	+0.8 +0.5%	**300.4** 52.1%
Total	808.8	**847.8**	100.0%	+39.0 +4.8%	**1,690.0** 50.2%

*1: R&D expenses, experimentation and research expenses, and development amortization
*2: Depreciation, goodwill amortization
*3: Commission expenses, consulting expenses
*4: Sales commissions, samples, advertising, and entertainment expenses

Personnel expenses | Personnel expenses increased by ¥1,870 million YoY due to increase in employees and base salary domestically and internationally.

Transportation expenses | Overseas freight charges in North, Central, and South America and Europe increased by ¥910 million YoY.

Promotion expenses | Exhibition costs for the Osaka-Kansai Expo pavilion and other factors increased ¥580 million YoY.

R&D Expenses

(¥ 100 million)	H1 FY03/25	H1 FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)
Medical (*1)	70.2	**74.6**	+4.4 +6.3%	151.7 49.2%
Pharmaceutical (*1)	45.2	**43.9**	-1.2 -2.8%	91.1 48.3%
Pharma Packaging (*1)	2.9	**2.3**	-0.5 -20.2%	7.2 32.6%
Total (*2)	118.4	**121.0**	+2.5 +2.1%	250.0 48.4%

(*1) The aggregation method has been revised based on the definition of R&D expenses in the accounting standards.
(*2) Including R&D expenses in manufacturing costs and SG&A Expenses.

Medical-Related | An increase of ¥440 million YoY due to Vascular product development and other factors.

Pharmaceutical-Related | A decrease of ¥120 million YoY duo to decrease in outsourced development expenses.

PharmaPackaging | A slight decrease compared to the previous year.

Capex and Depreciation

(¥ 100 million)	Capex				Depreciation			
	H1 FY03/25	H1 FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)	H1 FY03/25	H1 FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)
Medical-Related	205.8	**148.5**	-57.3 -27.9%	336.2 44.2%	165.6	**178.6**	+13.0 +7.9%	388.0 46.1%
Pharmaceutical-Related	115.8	**60.1**	-55.7 -48.1%	257.2 23.4%	75.1	**69.1**	-6.0 -8.0%	143.9 48.0%
PharmaPackaging	39.2	**24.6**	-14.5 -37.1%	62.2 39.7%	36.7	**29.6**	-7.0 -19.3%	69.7 42.5%
Other	17.4	**9.7**	-7.7 -44.0%	51.6 19.0%	24.8	**24.0**	-0.7 -2.9%	47.6 50.6%
Total	378.4	**243.1**	-135.3 -35.8%	707.1 34.4%	302.3	**301.5**	-0.8 -0.3%	649.2 46.4%

Capex

Medical-related investments, in total of ¥14,850 million, included about ¥3,000 million expanding a new dialyser line at the Odate Plant, ¥1,990 at Nipro Vietnam, and ¥2,380 million for equipment and supplies in the dialysis center. However, compared to the previous year, there was a decrease of ¥5,730 million due to the completion of dialyzer-related investments at the Odate Plant and Hefei Plant in the previous fiscal year.
Pharmaceutical-related investments included ¥3,100 million for the general pharmaceutical building at Nipro Pharma's Omi Plant and ¥430 million for the expansion of the Ise Plant. However, due to expansion investments at the Omi Plant in the previous fiscal year, there was a decrease of ¥5,570 million compared to the previous year.
PharmaPackaging investments, in total of ¥2,460 million, included ¥610 million in equipment investment in France, ¥730 million in capacity expansion in Germany, and ¥530 million in renovation investment in the U.S.. However, due to expansion investments in the U.S. and investments in syringe production expansion in Germany in the previous fiscal year, there was a decrease of ¥1,450 million yen compared to the previous year.

Depreciation

Although medical-related depreciation increased due to the establishment of a new seventh factory at the Odate Plant, depreciation expenses remained at the same level as the previous year due to a decrease in depreciation of Nipro Pharma's machinery and equipment related to pharmaceuticals, as well as impairment losses at PharmaPackaging in France.

P/L comparison excluding forex impact

(¥ 100 million)	H1 FY03/25 【a】	H1 FY03/26 【b】	Exchange rate Impact* 【c】	FY03/26 Results Excl. Impact 【d=b-c】	Change % 【d÷a】
Net sales	3,120.1	3,173.8	-63.3	**3,237.1**	+3.8%
Cost of sales	2,176.7	2,172.6	-40.8	**2,213.4**	
Gross profit	943.4	1,001.1	-22.4	**1,023.6**	+8.5%
(%)	30.2%	31.5%		**31.6%**	
SG&A expenses	808.8	847.8	-18.3	**866.2**	
Operating profit	134.5	153.3	-4.1	**157.4**	+17.0%
(%)	4.3%	4.8%		**4.9%**	
Non-operating income	26.0	25.1		**25.1**	
Non-operating expenses	115.7	96.2	-33.9	**130.1**	
Ordinary profit	44.9	82.3	+29.8	**52.5**	+16.9%
Extraordinary income	1.7	67.0		**67.0**	
Extraordinary losses	6.2	24.9		**24.9**	
Profit before tax	40.5	124.4	+29.8	**94.6**	+133.7%
Income taxes	32.3	58.1	+13.9	**44.2**	
Profit attributable to non-controlling interests	6.8	7.2		**7.2**	
Profit attributable to owners of perent	1.2	59.0	+15.8	**43.1**	+3239.3%

* Total foreign currency transactions converted to yen using the difference from previous year's rate. Forex impact on yen-denominated transactions has not been taken into account.

NIPRO

Segment Sales and Segment Profit

(¥ 100 million)

	Net sales				Segment Profit				
	1H FY03/25	1H FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)	H1 FY03/25	H1 FY03/26	Change (Change %)	FY03/26 Forecast as of May (Profit ratio)	FY03/26 Forecast as of November (Profit ratio)
Medical-Related segment	2,420.5	**2,525.6**	+105.1	5,334.2	245.4	**239.4**	-5.9	533.9	533.9
			+4.3%	47.3%	10.2%	9.5%	-2.4%	10.0%	10.0%
Pharmaceutical-Related segment	379.8	**370.8**	-8.9	863.7	31.9	**49.1**	+17.2	107.8	107.8
			-2.3%	42.9%	8.4%	13.3%	+54.0%	12.5%	12.5%
PharmaPackaging segment	315.9	**272.2**	-43.7	568.0	9.3	**- 8.6**	-17.9	3.5	-20.6
			-13.8%	47.9%	2.9%	-3.2%	-192.5%	0.6%	-3.6%





Medical-Related segment	Segment profit deceased by ¥590 million YoY due to increased depreciation, labor and personnel expenses, and transportation costs, despite rising sales and restrained increases in raw material costs.
Pharmaceutical-Related segment	Segment profit increased by ¥1,720 million YoY, driven by lower cost of sales due to reduced depreciation expenses, price increases reflecting higher raw material and labor costs, and the discontinuation of unprofitable products, despite a decrease in sales revenue.
PharmaPackaging segment	Segment profit decreased by ¥1,790 million YoY due to a decline in sales.

(1) Medical-Related Segment Sales (Domestic)

Net sales (¥ 100 million)	H1 FY03/25	H1 FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)
Domestic business	1,110.6	**1,128.6**	+17.9 +1.6%	2,439.8 46.3%
Medical devices	565.4	**577.9**	+12.4 +2.2%	1,261.7 45.8%
Pharmaceuticals	545.2	**550.1**	+4.9 +0.9%	1,178.1 46.7%

Quarterly Sales Trends



Medical devices

Sales of dialyzers decreased by ¥560 million YoY due to limited shipment of the Fineflux product.

Sales of dialysis equipment decreased by ¥300 million YoY due to a decrease in shipments.

Sales of injection needles and infusion-related products, due to the passing-through of costs, resulting in an increase of ¥860 million YoY for injection needles and an increase of ¥410 million YoY for infusion-related products.

Sales of vascular-related products enjoyed steady sales associated with market share resulted from indications for drug-eluting balloons helped its sales grow. Additionally, the newly launched peripheral balloon catheter products performed strongly, contributing to a ¥280 million YoY increase in sales.

Pharmaceuticals

Sales of oral medications decreased ¥1,150 million YoY due to the continued impact of consolidating loss-making items and decline in the NHI drug prices including esomeprazole.

Sales of injectable and infusion medications increased by ¥2,940 million YoY due to driven by the lifting of limited shipments for Tazopipe and normal saline syringes, as well as steady shipment volumes for Pegfilgrastim BS and Sugammadex.

Sales of topical medications and patches decreased by ¥890 million YoY due to the continued impact of decrease shipments of BudeForu Dry powder Inhaler and Loxoprofen Sodium tapes, despite the lifting of limited shipments in supply.

Sales of in vitro diagnostic products decreased by ¥410 million YoY, primarily due to sluggish sales of antigen test kits as infectious is currently under control.

(1) Medical-Related Segment Sales (Overseas)

Net sales (¥ 100 million)	1H FY03/25	1H FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)
Overseas business	1,309.5	**1,397.0**	+87.4 +6.7%	2,894.1 48.3%
B2B (other brands)	156.8	**166.1**	+9.2 +5.9%	355.9 46.7%
Nipro brands	1,152.6	**1,230.8**	+78.2 +6.8%	2,538.2 48.5%
Americas	486.7	**536.5**	+49.8 +10.2%	1,060.1 50.6%
Europe	258.5	**280.1**	+21.5 +8.3%	562.1 49.8%
Asia	242.1	**235.4**	-6.6 -2.7%	536.2 43.9%
China	165.2	**178.6**	+13.4 +8.1%	379.8 47.0%

Quarterly Sales Trends

(¥ 100 million)



B2B

Sales in B2B business increased by ¥920 million YoY due to stronger sales of SafeTouch PSV in Americas and Europe. Additionally, demand for GLP-1 specific needles is expected to remain at last year's level, although the proliferation of similar formulations has caused a decrease.

Nipro brand

Americas

Sales in Americas increased by ¥4,980 million YoY. Reasons are as follows:
Sales of dialyzer, dialysis machine and liquid dialysis solution increased due to reasons such as large contacts and tender activities.

Europe

Sales in Europe increased by ¥2,150 million YoY. Reasons are as follows:
Sales of dialyzers and vascular-related products increased. In addition, sales of dialysis machine increased in Western European Countries and Africa.
Sales of liquid dialysis solution increased in Western European countries, etc.

Asia

Sales in Asia decreased by ¥660 million YoY. Reasons are as follows:
Sales of dialyzers increased in Middle East region due to tender activities.
There were stronger sales in the Philippines due to establishment of new dialysis centers, driven by higher reimbursement price. On the other hand, sales of dialyzers decreased in Indonesia due to the policy impacts, the shift to single-use dialysis has proceeded at a slow pace, leading to temporary inventory adjustments. In addition, Sales of dialysis machines in India and Middle East decreased as a reaction to large tender activities in the last year.

China

Sales in China increased by ¥1,340 million YoY due to officially start of centralized procurement and an increase in sales volume of dialyzers. In addition, sales at dialysis centers remained strong due to an increase in the number of patients and the expansion of dialysis centers.

(2) Pharmaceutical-Related Segment Sales

Net sales (¥ 100 million)	H1 FY03/25	H1 FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)
Pharmaceutical-Related	379.8	**370.8**	-8.9 -2.3%	863.7 42.9%
Generic drugs	161.7	**159.8**	-1.8 -1.1%	318.7 50.2%
Brand-name drugs Long-listed drugs	159.0	**162.3**	+3.2 +2.1%	430.6 37.7%
OTC drugs Active ingredients, etc.	20.7	**11.9**	-8.7 -42.4%	37.5 31.8%
JMI Pharma	38.3	**36.7**	-1.5 -4.1%	76.9 47.8%

Quarterly Sales Trends

(¥ 100 million)



Generic drugs

Sales of injections increased by ¥680 million YoY due to higher orders for key anticancer drugs.

Sales of oral drugs decreased by ¥420 million YoY due to lower orders.

Sales of external preparations decreased by ¥450 million YoY due to the discontinuation of contracted products.

Brand-name/long-listed drugs

Sales of injections increased by ¥1,400 million YoY, primarily due to growth in sales of newly contracted products, increased orders for existing products, and the passing on of costs.

Sales of oral drugs decreased by ¥450 million YoY, mainly because orders for long-listed drugs declined due to the impact of the Selected Medical Care System.

Sales of external preparations decreased by ¥620 million YoY due to lower orders.

OTC drugs, active ingredients, etc.

Sales decreased by ¥870 million YoY due to the discontinuation of commissioned OTC external preparations.

(3) PharmaPackaging Segment Sales

Net sales (¥ 100 million)	H1 FY03/25	H1 FY03/26	Change (Change %)	FY03/26 Forecast (Achievement %)
PharmaPackaging	315.9	**272.2**	-43.7 -13.8%	567.9 47.9%
Japan	74.0	**76.1**	+2.1 +2.9%	145.9 52.2%
Overseas	241.9	**196.0**	-45.8 -19.0%	422.0 46.5%
Europe	147.3	**127.7**	-19.5 -13.3%	286.5 44.6%
United States	70.2	**53.0**	-17.2 -24.5%	117.1 45.3%
China	15.0	**8.9**	-6.0 -40.1%	4.3 209.3%
India	9.3	**6.2**	-3.0 -32.7%	13.9 45.2%

Quarterly Sales Trends



Japan

Mainly due to increase of glass tubing sales after successful price increase and strong sales growth of dental related products field, resulted in an overall increase of sales by ￥210 million YoY.

Overseas

Europe

Growth in sales of double tip ampoules was made possible by the strategy of our sales team, meanwhile sales of sterilized syringes, which performed well last fiscal year, declined due to intense competition with new entrants to the market, resulted in an overall decrease of sales by ￥1,950 million YoY.

United States

Steady glass tubing sales for biopharmaceutical-related purposes, on the other hand, vials sales was still under impact of global market destocking, resulted in an overall decrease of sales by ￥1,720 million YoY.

Appendix

Exchange rate, sensitivity / Product Category

<Average rate>

	FY2024				FY2025				
	Jan-Mar	Jan-Jun	Jan-Sep	Jan-Dec	Jan-Mar	Jan-Jun	Jan-Sep	Jan-Dec	Forecast
¥/USD	149.88	154.06	151.59	152.24	151.21	147.48	–	–	139.00
¥/EUR	162.15	166.12	164.61	164.36	159.35	162.24	–	–	158.00
¥/CNY	20.74	21.25	21.05	21.12	20.75	20.34	–	–	20.00

<Closing rate>

	FY2024 As of Sep.30	FY2025 As of Sep.30
¥/USD	142.73	148.88
¥/EUR	159.43	174.47
¥/CNY	20.46	20.88

<Estimates of Forex sensitivity>

¥100M	Net Sales	Operating Profit
¥/USD	10.1	0.5
¥/EUR	6.0	2.3
¥/CNY	18.4	8.4

<Product Category>

Medical devices	
Dialyzers	Dialyzers (artificial kidneys), HDF filters
Dialysis equipment	Dialysis systems, maintenance, dialysis equipment parts
Other dialysis-related products	Blood circuits, AVF needles, etc.
Needles	PSV needles, safetouch needles, etc.
Vascular products	Catheter sets for cardiovascular treatments, thrombus aspiration catheters, etc.
Infusion-related products	Infusion sets, IV cannulas, etc.
Testing products	Neotube (vacuum blood collection tube), etc.
Diabetes-related products	Insulin needles, blood glucose meters (for overseas markets), lancets
Surgical device-related products	Mechanical circulatory support, cardiopulmonary bypass products
Other products	Medical instruments, blood-related products, cell culture-related products, gloves, etc.

Pharmaceuticals	
Oral drugs	Oral drugs
Injection and infusion products	Syringe kits, vial formulations, dual chamber bags (PLW), powdered dialysate, dialysis fluids, etc.
External preparations and patches	External preparations, patches
Others, in vitro diagnostics, etc.	Reagents, pharmaceuticals, blood glucose meters, etc.

PharmaPackaging	
Glass tubing-related products	Medical-use glass tubing, non-medical use glass tubing
Glass ampoules	Ampoules (single tip, double tip)
Glass vials	Vials (blowback, screw, etc.)
Glass syringes	Syringes (luer lock, luer slip, sterilized, etc.)
Rubber stoppers and plugs	Rubber stoppers, plugs, closures, and caps
Plastic containers	Plastics
Thermos bottles	Glass for thermos bottles
Other products	Glass containers and others, special glass containers, cartridge glass and others, etc.

Net Sales by Segment and Product Category

Product \ Segment (¥ 100 million)		Medical -Related	Pharmaceutical -Related	Pharma Packaging	Other	Total
Medical devices	**H1 FY03/26**	**1,884.4**	**-**	(*3) **23.0**	**-**	**1,907.5**
	H1 FY03/25	1,801.3	-	(*3) 22.9	-	1,824.3
Pharmaceuticals	**H1 FY03/26**	(*1) **641.1**	(*2) **370.8**	**4.7**	**-**	**1,016.8**
	H1 FY03/25	(*1) 617.4	(*2) 379.8	3.1	-	1,000.4
Pharma Packaging	**H1 FY03/26**	**-**	**-**	**243.8**	**-**	**243.8**
	H1 FY03/25	1.5	-	289.1	-	290.6
Other	**H1 FY03/26**	**0.0**	**-**	**0.5**	**4.9**	**5.6**
	H1 FY03/25	0.1	-	0.7	3.8	4.7
Total	**H1 FY03/26**	**2,525.6**	**370.8**	**272.2**	**4.9**	**3,173.8**
	H1 FY03/25	2,420.5	379.8	315.9	3.8	3,120.1

*1: In-house generic drugs
*2: Contract manufacturing of pharmaceuticals
*3: Needles, infusion-related products, testing products

Net Sales by Segment and Region

Region / Segment (¥ 100 million)		Medical -Related	Pharmaceutical -Related	Pharma Packaging	Other	Total
Japan	**H1 FY03/26**	**1,130.7**	**331.6**	**76.2**	**4.8**	**1,543.5**
	H1 FY03/25	1,112.6	337.6	74.1	3.8	1,528.2
Overseas Total	**H1 FY03/26**	**1,394.9**	**39.2**	**195.9**	**0.1**	**1,630.3**
	H1 FY03/25	1,307.8	42.1	241.8	-	1,591.9
Americas	**H1 FY03/26**	**590.1**	**-**	**52.0**	**0.1**	**642.2**
	H1 FY03/25	533.1	-	69.0	-	602.2
Europe	**H1 FY03/26**	**348.3**	**2.1**	**127.0**	**-**	**477.5**
	H1 FY03/25	311.9	1.6	145.6	-	459.2
China	**H1 FY03/26**	**179.6**	**0.1**	**9.4**	**-**	**189.2**
	H1 FY03/25	167.1	0.2	15.0	-	182.3
Asia Other	**H1 FY03/26**	**276.8**	**37.0**	**7.4**	**-**	**321.2**
	H1 FY03/25	295.5	40.3	12.1	0.0	348.0
Total	**H1 FY03/26**	**2,525.6**	**370.8**	**272.2**	**4.9**	**3,173.8**
	H1 FY03/25	2,420.5	379.8	315.9	3.8	3,120.1

NIPRO

Net Sales by Product Category (1)

Business Category	(¥ 100 million)	Overall				Overseas				Japan			
		H1 FY03/25	H1 FY03/26	Change	Change %	H1 FY03/25	H1 FY03/26	Change	Change %	H1 FY03/25	H1 FY03/26	Change	Change %
Medical devices	Dialyzers	519.3	548.5	+29.1	+5.6%	405.8	440.6	+34.7	+8.6%	113.4	107.8	-5.5	-4.9%
	Dialysis equipment	134.4	146.9	+12.5	+9.3%	102.2	117.7	+15.4	+15.2%	32.2	29.2	-2.9	-9.2%
	Other dialysis-related products	299.1	319.2	+20.0	+6.7%	257.0	275.8	+18.8	+7.3%	42.1	43.3	+1.1	+2.8%
	Dialysis-related products total	**952.9**	**1,014.7**	**+61.7**	**+6.5%**	**765.1**	**834.2**	**+69.1**	**+9.0%**	**187.8**	**180.4**	**-7.3**	**-3.9%**
	Needles＊	289.8	314.2	+24.4	+8.4%	196.2	211.4	+15.2	+7.7%	93.6	102.8	+9.2	+9.9%
	Vascular products	168.1	174.6	+6.4	+3.9%	46.5	49.2	+2.6	+5.7%	121.6	125.4	+3.8	+3.2%
	Infusion-related products	119.2	122.6	+3.3	+2.8%	50.9	50.6	-0.2	-0.5%	68.3	71.9	+3.6	+5.3%
	Testing products＊	37.4	36.9	-0.5	-1.5%	21.1	18.3	-2.7	-12.9%	16.3	18.5	+2.1	+13.2%
	Diabetes-related products	64.0	60.2	-3.7	-5.9%	58.0	53.6	-4.3	-7.6%	6.0	6.6	+0.6	+10.0%
	Surgical device-related products	49.6	51.4	+1.7	+3.6%	11.7	12.3	+0.6	+5.5%	37.9	39.0	+1.1	+3.0%
	Other products	140.5	128.9	-11.6	-8.3%	84.2	73.9	-10.3	-12.2%	56.3	55.0	-1.2	-2.3%
	Category Total	**1,822.0**	**1,903.9**	**+81.8**	**+4.5%**	**1,233.9**	**1,303.8**	**+69.9**	**+5.7%**	**588.1**	**600.0**	**+11.9**	**+2.0%**
Pharmaceuticals (own brand)	Oral drugs	236.2	224.7	-11.4	-4.9%	0.1	0.1	+0.0	+1.8%	236.0	224.5	-11.4	-4.9%
	Injection and infusion products	289.9	338.2	+48.2	+16.7%	70.3	89.2	+18.8	+26.8%	219.5	248.9	+29.4	+13.4%
	External preparations and patches	35.7	26.7	-8.9	-25.0%	-	-	-	-	35.7	26.7	-8.9	-25.0%
	Others, in vitro diagnostics, etc.	55.6	51.4	-4.2	-7.6%	1.7	1.5	-0.1	-8.2%	53.8	49.8	-4.0	-7.5%
	Category Total	**617.4**	**641.1**	**+23.6**	**+3.8%**	**72.2**	**90.9**	**+18.7**	**+25.9%**	**545.1**	**550.1**	**+4.9**	**+0.9%**
Regenerative medicines	**Regenerative medicine products**	**2.2**	**3.6**	**+1.3**	**+59.5%**	**-**	**-**	**-**	**-**	**2.2**	**3.6**	**+1.3**	**+59.5%**

＊Phlebotomy needles etc. included in “testing products” have been changed to “Needles.” from this fiscal year.

Net Sales by Product Category (2)

Business Category	(¥ 100 million)	Overall H1 FY03/25	Overall H1 FY03/26	Overall Change	Overall Change %	Overseas H1 FY03/25	Overseas H1 FY03/26	Overseas Change	Overseas Change %	Japan H1 FY03/25	Japan H1 FY03/26	Japan Change	Japan Change %
Pharmaceuticals (contract manufacturing)	Oral drugs	139.5	130.8	-8.6	-6.2%	0.3	0.2	-0.1	-33.0%	139.1	130.6	-8.5	-6.2%
	Injection and infusion products	160.1	183.3	+23.2	+14.5%	2.8	1.6	-1.2	-41.7%	157.2	181.6	+24.4	+15.5%
	External preparations and patches	33.1	14.9	-18.2	-55.0%	0.3	0.3	+0.0	+0.4%	32.8	14.6	-18.2	-55.5%
	Others, in vitro diagnostics, etc.	11.8	9.7	-2.0	-17.1%	+0.3	0.3	+0.0	-	11.4	9.4	-2.0	-17.6%
	Category Total	**344.6**	**338.9**	**-5.7**	**-1.7%**	**3.8**	**2.5**	**-1.3**	**-34.0%**	**340.8**	**336.3**	**-4.4**	**-1.3%**
Pharmaceuticals (JMI Pharma)	Oral drugs	37.9	36.3	-1.6	-4.3%	37.9	36.3	-1.6	-4.3%	-	-	-	-
	Injection and infusion products	0.3	0.3	+0.0	+9.2%	0.3	0.3	+0.0	+9.2%	-	-	-	-
	Category Total	**38.3**	**36.7**	**-1.5**	**-4.1%**	**38.3**	**36.7**	**-1.5**	**-4.1%**	**-**	**-**	**-**	**-**
Pharma Packaging	Glass tubig-related products	71.1	62.7	-8.3	-11.7%	58.1	49.2	-8.9	-15.3%	12.9	13.5	+0.5	+4.3%
	Glass ampoules	45.4	39.1	-6.2	-13.7%	45.3	39.0	-6.2	-13.7%	0.1	0.0	+0.0	-15.2%
	Glass vials	85.1	61.1	-23.9	-28.1%	74.9	50.8	-24.0	-32.1%	10.1	10.3	+0.1	+1.1%
	Glass syringes	52.2	39.8	-12.4	-23.7%	52.2	39.6	-12.5	-24.0%	0.0	0.1	+0.1	+166.9%
	Rubber stoppers and plugs	7.1	7.7	+0.6	+8.5%	0.0	0.0	+0.0	+157.6%	7.1	7.7	+0.5	+8.2%
	Plastic containers	10.5	10.6	+0.0	+0.7%	0.0	-	+0.0	-100.0%	10.5	10.6	+0.0	+0.7%
	Thermos bottles	2.8	2.9	+0.0	+3.1%	-	-	-	-	2.8	2.9	+0.0	+3.1%
	Other products	16.1	19.4	+3.3	+20.7%	12.5	16.7	+4.1	+33.1%	3.5	2.7	-0.8	-23.1%
	Category Total	**290.6**	**243.8**	**-46.8**	**-16.1%**	**243.1**	**195.6**	**-47.5**	**-19.5%**	**47.4**	**48.1**	**+0.6**	**+1.5%**
Other	**Sales of production machinery and real estate leasing**	**4.7**	**5.6**	**+0.8**	**+18.8%**	**0.3**	**0.5**	**+0.1**	**+45.5%**	**4.3**	**5.1**	**+0.7**	**+16.7%**
	Consolidated Total	**3,120.1**	**3,173.8**	**+53.6**	**+1.7%**	**1,591.9**	**1,630.3**	**+38.4**	**+2.4%**	**1,528.2**	**1,543.5**	**+15.2**	**+1.0%**

Forecasts and other forward-looking statements in this document are based on information currently available to the Company and certain assumptions that the Company believes to be reasonable.
Actual results may differ materially from those described in this document due to various factors that may arise in the future.
This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

NIPRO

Live Longer. Live Better.